Kornimate/medical-research-clean huggingface dataset:
pancreatic stent to prevent leak after distal pancreatectomy

Conditions: Pancreatic Surgery; Pancreatic Duct Stenting; Pancreatic Cancer; Distal Pancreatectomy; Pancreatic Diseases; Pancreatic Cyst; Pancreatic Ducts

Summary: the purpose of this study is to investigate an intervention to prevent complications after pancreas surgery. the goal is to determine if placing a stent into the pancreatic duct before surgery will decrease or prevent leaking from the pancreatic duct after surgery. leaks are common after pancreas surgery and can result in serious problems and post-operative pain. the study will compare two groups. one group will have the stent before surgery, and the other group will have standard pancreas surgery, no endoscopy, and no stent.


Eligibility criteria:
inclusion criteria: * adult patients (greater than or equal to 18 years of age) * scheduled to undergo an elective laparoscopic or open distal pancreatectomy * willing to undergo pre-operative endoscopy * consenting to the procedure exclusion criteria: * contraindication to abdominal surgery * contraindication to general anesthesia or distal pancreatectomy * contraindication to upper endoscopy or ercp * prior history of gastric bypass or other abdominal surgery in whom the ampulla will not be accessible via routine ercp * ongoing pancreatitis * pancreatic necrosis or abscess * history of sphincter of oddi dysfunction * history of ercp-induced pancreatitis

Keywords: pancreas surgery pancreatic adenocarcinoma pancreatic neuroendocrine tumor pancreatic duct stenting
comparison of infiltration analgesia with femoral nerve block after hamstrings anterior cruciate ligament reconstruction

Conditions: Injury of Anterior Cruciate Ligament

Summary: pain treatment after anterior cruciate ligament reconstruction - comparison of infiltration analgesia with femoral nerve block after.

inclusion criteria: * patients undergoing primary anetrior cruciate ligament reconstruction with semitendinos/gracillis graft * age \> 18 year exclusion criteria: * revision acl reconstruction * patients with cartilige lision * patients with arthritis * pregnant women.

Eligibility criteria:
inclusion criteria: * patients undergoing primary anetrior cruciate ligament reconstruction with semitendinos/gracillis graft * age \> 18 year exclusion criteria: * revision acl reconstruction * patients with cartilige lision * patients with arthritis * pregnant women.
muscle wasting in children and adolescents with cancer

Conditions: Cachexia; Cancer; Muscle Wasting; Child Development; Adolescent Development

Summary: the series of the 3-year study aims to explore parents' experience of caring for a child's weight change among parents of children and adolescents with cancer, examine the associations and trends among muscle wasting and health-related variables, and then implement and assess effectiveness of a multidisciplinary approach with a personalized physical activity (walking) training intervention on improving muscle mass and other health-related variables.

specific aims, year by year 1. the aim for year 1 is as follows: aim 1: to explore parents' experience of caring for promoting a child's exercise among parents of children and adolescents with cancer. 2. the aims for year 2 are as follows: aim 2-1: to examine the associations between the degree of muscle wasting and health-related variables (fatigue level, symptom distress level, physical activity involvement, dietary intake, and qol) among children and adolescents with cancer. aim 2-2: to examine the trends of changes in muscle wasting and health-related variables (fatigue level, symptom distress level, physical activity involvement, dietary intake, and qol) during the first 6 months of cancer treatment among children and adolescents with cancer. 3. the aim for year 3 is as follows: aim 3: to examine the effectiveness of a multidisciplinary approach with a personalized walking exercise program on changes in body composition and health-related variables (fatigue level, symptom distress level, subjective physical activity involvement, objective physical activity measurement, dietary intake, and qol) among children and adolescents with cancer.

Eligibility criteria:
inclusion criteria: * aim 1:(1) parents of children diagnosed with malignancies at 3-18 years old, (2) whose children have received cancer treatment for at least 6 months, (3) who are the main caregivers, and (4) who are willing to participate in the study. * aim 2-1:(1) children and adolescents diagnosed with malignancies at 3-18 years old, (2) who are previously or currently treated for cancer, and (3) who are willing to participate in the study. two hundred patients will be recruited. * aim 2-2:(1) children and adolescents diagnosed with malignancies at 3-18 years old, (2) newly diagnosed with cancer within the past 1 month, and (3) willing to participate in the study. one hundred participants will be recruited. * aim 3:(1) children and adolescents aged 3-18 years old and are undergoing treatment, and (2) who are willing to participate in the study. exclusion criteria: -aim 1-3: children and adolescents are under poor physical or cognitive conditions.

Keywords: symptom distress nutrition physical activity body composition children and adolescents cancer nursing care
pet-guided radiotherapy for patients with small cell lung cancer.

Conditions: Small Cell Lung Carcinoma

Summary: there is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary s3 guideline of the german cancer society/cancer aid/awmf

the main objective of this study is to determine whether patients with sclc who have a metabolically active residual tumor in the fluorodeoxyglucose (fdg) pet/ct scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. there is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary s3 guideline of the german cancer society/cancer aid/awmf. allocation to pet boost, if confirmed vital tumor rest by pet ct and biopsy.

Eligibility criteria:
inclusion criteria: * histopathologic confirmation * limited disease exclusion criteria: * other histology than small cell lung cancer * further tumor diagnosis * ecog 3 or worse * extensive disease * stage iv
mobile subthreshold exercise program for concussion

Conditions: Brain Concussion

Summary: non-randomized pilot intervention using mobile-administered sub-threshold exercise to treat youth with prolonged symptoms of concussion.

6-week pilot study of a novel intervention for concussion, administering a sub-threshold exercise program in a mobile fashion using video conferencing and providing feedback using wrist-worn accelerometry and heart rate monitoring.

Eligibility criteria:
inclusion criteria: * concussion diagnosed by a healthcare provider that occurred 2 weeks-6 months ago * continued symptoms with at least 3 symptoms on the hbi and a score of 20+ * no other issues that would preclude physical activity * parents and youth are english-speaking exclusion criteria: - already participating in \>30 minutes of mvpa/day

Keywords: child adolescent exercise rehabilitation physical activity virtual mobile health
pharmacokinetics of intravenous difelikefalin in chinese adult subjects on haemodialysis

Conditions: End Stage Renal Disease on Hemodialysis

Summary: this is a phase 1, single-arm, open-label study to evaluate the safety, pk, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as iv bolus injections to adult chinese hd subjects. treatment period is one week and there is a safety follow-up period of 1 week.

this is a phase 1, single-arm, open-label study to evaluate the safety, pk, and tolerability of a repeated (3 times weekly) dose of difelikefalin administered as iv bolus injections to adult chinese hd subjects. total study duration for a single subject is up to 5 weeks including a screening period of up to 3 weeks, a treatment period of 1 week, and a safety follow-up period of 1 week. the duration of pk sampling is 12 days. the primary objective of the study is to evaluate the pk profile of a repeated (3 times weekly) dose of difelikefalin in chinese hd subjects over a 1-week treatment period.

Eligibility criteria:
inclusion criteria: * end-stage renal disease (esrd) subjects who have been on hd for at least 3 months before enrolment in the study and are currently on hd 3 times per week. * subjects with a prescription dry body weight between 40 and 100 kg, inclusive. * if female, is not pregnant, or nursing * if female: 1. is surgically sterile; or 2. has been amenorrhoeic for at least 1 year and is over the age of 55 years; or 3. has a negative serum pregnancy test within 7 days before first dose of investigational product, and agrees to use adequate contraceptive precautions (e.g., hormonal contraceptives, barrier with spermicide, intrauterine device, vasectomised partner, or abstinence) from the time of informed consent until 7 days after the last dose of investigational product. * if male, agrees not to donate sperm from the first dose of investigational product administration (day 1) until 7 days after last dosing, and agrees to use a condom with spermicide or abstain from heterosexual intercourse during the study until 7 days after the last dose of investigational product. exclusion criteria: * planned or anticipated to receive a kidney transplant during the study. * serum alanine aminotransferase (alt), aspartate aminotransferase (ast) greater than 2.5 × the reference upper limit of normal (uln), or bilirubin (total) greater than 4 × the uln at screening. * subjects with severe hepatic impairment (child-pugh class c). * known history of allergic reaction to opiates such as hives. note: side effects related to the use of opioids such as constipation or nausea would not exclude the subjects from the study. * subject has known hypersensitivity to the study intervention or any component of the investigational product formulation.

Keywords: difelikefalin pharmacokinetics
clinical trial on individual characteristics affecting pain drug therapy in neonates

Conditions: Critical Illness

Summary: children differ from adults with respect to growth and development but also immaturity of various pharmacological mechanisms. dosing schemes in children are usually derived in an empirical manner from clinical trials in adult patient groups. all this poses neonates to an increased risk for therapeutic failure and adverse drug reactions. medicinal products studied during this project are among the ones with the highest needs for research in the pediatric intensive care. this project focuses on the necessity to integrate subject's individual characteristics to assist clinical decision-making in drug therapy. the investigators explore the mechanisms defining the dose response in pediatric populations. the results obtained with these studies will help to find safer drug dosing regimens in this delicate patient population.


Eligibility criteria:
inclusion criteria: * given informed consent by the guardian of an eligible patient. * patient is more than 24 weeks old and has a body weight more than 500 g. * patient needs intensive care treatment based on a clinical decision by a neonatologist and receives propofol or oxycodone on their therapy. attending neonatologist makes the decision to prescribe propofol for scheduled short procedural sedation or oxycodone for analgesia as well as all other treatment related decisions. exclusion criteria: * eligible patients guardian declines to give informed consent. * a previous history of intolerance to the study drugs or to related compounds and additives. * history of any kind of drug allergy. * participation in any other studies concomitantly or within one month prior to the entry into this study.

Keywords: neonatal intensive care need for intratracheal intubation
pharmacokinetic interactions and safety study of telmisartan and chlorthalidone

Conditions: Hypertension

Summary: clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan and chlorthalidone.


Eligibility criteria:
inclusion criteria: 1. healthy male subjects 2. age(yr)between 20 and 50 3. signed written informed consent exclusion criteria: 1. known hypersensitivity to investigator product, thiazide, sulphonamide and other drugs or additive. 2. history of any siginificant sickness, cardiovascular, respiratory, renal, endocrine, neurological, psychic, cancer, gasstrointestinal, hematologic. 3. history of drug and/or alcohol abuse 4. over 10 tobaccos a day 5. other condition which in the opinion of the investigator preclude enrollment into the study

Keywords: pharmacokinetics safety male
oxaliplatin in rectal cancer

Conditions: Rectal Neoplasms

Summary: * phase i: to determine the maximum tolerated dose, and recommended dose of the proposed doses of oxaliplatin in this study * phase ii: to determine the treatment efficacy according to response rates from phase i.


Eligibility criteria:
the following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. this information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional. main criteria are listed hereafter: inclusion criteria: * ecog: 0-2 * histological proved rectal adenocarcinoma * no chemotherapy treatment on the previous 6 months before inclusion. * no previous pelvic radiotherapy treatment exclusion criteria: * important biological abnormality (renal, hepatic and/or hematological) * intestinal occlusion or subocclusion * peripheral neuropathy * pregnant or breast-feeding women. potential child-bearing women with a positive pregnancy test. * participation in other trials on the previous 4 months.
the effect of combined 650 nm and infrared laser on chronic diabetic foot ulcer surface area:

Conditions: Diabetic Foot; Wound Heal

Summary: objective: investigate the effect of combined 650 nm and infrared laser on chronic diabetic foot ulcer surface area. participants: the forty five patients will assigned randomly into three equal groups, each group consist of 15 patients, group a received laser therapy in sequential mode, group b received laser therapy in separate mode and the control group c receive traditional wound care

objective: investigate the effect of combined 650 nm and infrared laser on chronic diabetic foot ulcer surface area. participants: the forty five patients will assigned randomly into three equal groups, each group consist of 15 patients, group a received laser therapy in sequential mode, group b received laser therapy in separate mode and the control group c receive traditional wound care outcomes: the primary outcomes were the wound surface area measurement, % of wound complete closure and % of days needed for surface area reduction before and after receiving the treatment protocol for two consequetive months, and the secondary outcomes were % of wound cause and location frequencies

Eligibility criteria:
inclusion criteria: * 1- diabetic patients with either type i or ii 2- age from 18-60 years old, both sexes 3- ulcer lasting longer than two months 4- dfu grade 1 or 2 according to wagner classification. 5- all patients able to walk dependently exclusion criteria: 1. patients with vascular disease 2. patients with fixed ankle deformity as charcot foot or stiffness 3. patients with any type of osteomyelitis associated with dfu 4. patients with renal or hepatic failure 5. bmi \< 30 kg/m2 as obesity can cause poor perfusion due to vascular insufficiencies; altered population of immune mediators may lengthen the inflammatory process \& decrease oxygenation of subcutaneous adipose tissue which is liable to be infected.

Keywords: 650 nm laser infrared laser chronic diabetic foot ulcer wound surface area
cell therapy in severe chronic ischemic heart disease

Conditions: Chronic Ischemic Heart Disease; Coronary Artery Disease; Angina Pectoris

Summary: patients with advanced coronary artery disease usually undergo incomplete myocardial revascularization due to the extension and diffuseness of the disease, with very poor distal arterial beds unsuitable for direct revascularization. this study was designed to test the hypothesis that direct, intramyocardial injection of autologous bone marrow cells may further improve myocardial perfusion in patients undergoing incomplete bypass surgery.

all eligible patients will undergo coronary artery bypass grafting (cabg) and, in previously identified areas of viable, ischemic myocardium unsuitable for direct revascularization, be randomized to either placebo (saline) or intramyocardial injection of bone marrow-derived cells (bmc) during surgery. during follow-up, myocardial perfusion assessment will be performed to determine the improvement in treated areas compared to non-treated segments.

Eligibility criteria:
inclusion criteria: * symptoms of angina or angina equivalent * documented coronary artery disease (invasive angiography) * documented myocardial ischemia (stress echo, cardiac scintigraphy, or mri) * unsuitable for complete myocardial revascularization (pci or cabg) or even if a complete procedure in feasible, it is anticipated that myocardial perfusion may not be restored due to poor distal beds exclusion criteria: * severe lv dysfunction (ef \< 25% on echo) * short life expectacy (below \< 1 year) * diagnosis of cancer in the past 5 years * diagnosis of hematological diseases * diagnosis of severe heart disease of other etiologies including valvular heart disease, chagas' disease, etc) * diagnosis of acute coronary syndrome in the past 3 months * diagnosis of chronic kidney disease stage v requiring chronic dialysis

Keywords: chronic ischemic heart disease coronary artery disease angina pectoris myocardial ischemia cardiac surgery
pharmacist management of paxlovid evisits

Conditions: COVID-19; Quality of Care

Summary: the goal of this cluster randomized trial is to compare two modes of management -- pharmacist care vs. pooled adult and family medicine physician care -- for electronically submitted requests (e-visits) for paxlovid by adults with covid-19. it will compare quality of care based on counseling for common potential drug-drug interactions and time to prescription, as well as the time and financial costs of care in the two groups.

importance. enhancing the management of messages from patients and providing virtual options for urgent care are top priorities for the permanente medical group (tpmg) and kaiser foundation hospitals/health plan (kfh/p). objective. to compare pharmacist management of e-visit requests for paxlovid for covid-19 with management by adult and family medicine physician pools regarding costs, time, clinical outcomes, and patient and clinician satisfaction. design, setting, and participants. this cluster randomized clinical trial will include adults from 17 medical facilities of kaiser permanente northern california who make paxlovid e-visits on weekdays from october 9 to december 11, 2023. intervention. in the intervention group, a regional team of pharmacists will manage paxlovid e-visits following a standard protocol; in the comparison group, adult and family medicine physicians (afms) will manage these visits according to medical center-based protocols. main outcomes and measures. the primary outcome is whether a patient with one or more common drug-drug interactions received counseling for any drug-drug interaction. secondary outcomes are the hours from the e-visit request to the prescription among patients who receive one and the clinician time and cost per visit managed. potential results. we will test the hypotheses that pharmacist care compared with afm pool care will have higher quality of care and lower costs based on the receipt of counseling for common drug-drug interactions, faster time to prescriptions, and lower clinician time and cost per visit managed. potential conclusions and relevance. if pharmacist management has better or similar outcomes compared with afm pool management, this will provide support to continue this practice for paxlovid e-visits and to evaluate possible expansion of pharmacist management for similar clinical situations.

Eligibility criteria:
inclusion criteria: * patients making paxlovid e-visits on weekdays from 8:00 am to 4:30 pm during the study period exclusion criteria: * none
study of eltrombopag in healthy subjects and volunteers with mild, moderate or severe hepatic impairment

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Summary: the main purpose of this study is to compare how one 50mg tablet of sb-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. the study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.


Eligibility criteria:
inclusion criteria: * healthy or have liver impairment * females(the following requirement applies only if able to have children): agree to doctor approved birth control methods, or partner has had a vasectomy. * body mass index (bmi-within acceptable range) * negative drug, alcohol, and hiv tests exclusion criteria: * taking a medication or therapy not approved by the study doctor * rapidly changing liver function * kidneys not working well * drug or alcohol abuse within past 6 months * used an investigational drug in the past 30 days * females that are pregnant or nursing * have active hepatitis b or c * history of blood disorders * history of various heart conditions (as noted by study doctor) * blood clotting problems or blood abnormalities

Keywords: hepatitis c-associated thrombocytopenia chemotherapy induced thrombocytopenia thrombocytopenia hepatic impairment chronic immune thrombocytopenia purpura